PARP1 and cancer: Recent reports suggest that combining PARP inhibitors (PARPi) with select drugs may be effective in BRCA-proficient cancer cells, supporting the idea that novel PARPi combination approaches may fulfill the unmet therapeutic need in TNBC [7].